Preoperative chemoradiation therapy combined with peptide vaccination for T3-pancreatic cancer: prospective phase I/II study

Preoperative chemoradiation therapy combined with peptide vaccination for T3-pancreatic cancer: prospective phase I/II study - Preoperative multimodal treatment for pancreatic cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004422

Enrollment

Registered

2010-10-20

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T3(UICC)-pancreatic cancer

Interventions

Preoperative gemcitabine-based chemoradiation therapy with peptide vaccination Preoperative gemcitabine-based chemoradiation therapy without peptide vaccination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Resectable Pancreatic cancer ; T3 of UICC TNM classification of malignant tumours 7th edition). Histological or cytological confirmation as pancreatic adenocarcinoma is required. No contraindication for gemcitabine-based chemoradiation therapy.

Exclusion criteria

Exclusion criteria: Liver, renal dysfunction, severe coronary disease. Unresectable pancreatic cancer, including borderline resectable cases.

Design outcomes

Primary

Measure	Time frame
Safety Disease free survival	—

Secondary

Measure	Time frame
Overall survival, Histopathological and immunological response, pattern of recurrence	—

Countries

Japan

Contacts

Public ContactHidenori Takahashi

Osaka Medical Center for Cancer & Cardiovascular Diseases Department of Gastroenterological surgery

takahasi-hi@mc.pref.osaka.jp06-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026